Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | 3-oxoacyl-[acyl-carrier-protein] synthase III | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Conserved hypothetical protein | 3-oxoacyl-[acyl-carrier-protein] synthase III | 317 aa | 265 aa | 26.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0825 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0036 | 0.0454 | 0.4076 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.0727 | 0.6521 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0046 | 0.0727 | 0.5013 |
Schistosoma mansoni | bromodomain containing protein | 0.0064 | 0.1214 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0039 | 0.052 | 0.2673 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.0641 | 0.4395 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0825 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 1 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0036 | 0.0454 | 0.4076 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0825 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.0522 | 0.3541 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0383 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0825 | 0.5 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0023 | 0.0082 | 0.0739 |
Schistosoma mansoni | hypothetical protein | 0.0021 | 0.0029 | 0.0242 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0383 | 1 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.0727 | 0.6521 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0023 | 0.0082 | 0.0679 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0383 | 1 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.0727 | 0.5987 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0383 | 1 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.0727 | 0.5987 |
Brugia malayi | Bromodomain containing protein | 0.0076 | 0.154 | 1 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0023 | 0.0082 | 0.0739 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0046 | 0.0727 | 0.4159 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0383 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0588 | 0.4014 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.1421 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.005 | 0.0825 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.0727 | 0.5987 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.0727 | 0.6521 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.0727 | 0.6521 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.006 | 0.1115 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 1 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.006 | 0.1115 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 6.35 ug ml-1 | Inhibition of Escherichia coli Beta-ketoacyl-ACP synthase III expressed in Escherichia coli BL21 (DE3) by liquid scintillation counting | ChEMBL. | 19884012 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.